Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

Tools and Resources for You and Your Patients

Use the information below to learn why TAKHZYRO is a proven preventive treatment for HAE and how to create effective HAE management plans for your patients. You'll also find resources you can share with your patients and their caregivers to help them start and stay on TAKHZYRO.

Understand the burden of HAE further

HAE Assessment Patient Questionnaire.

Hereditary Angioedema (HAE) Assessment Questionnaire for Patients

Use this comprehensive list of
questions about HAE's impact
on your patients to help
guide your initial assessment.

DOWNLOAD

TAKHZYRO® Conversation Starter.

Doctor Discussion Guide

See how your patients might start the conversation about TAKHZYRO.

DOWNLOAD

HAE Attack Plan.

HAE Attack Plan

Fill out this form with your patient to help them explain HAE to others, including what steps to take in the event of an emergency.

DOWNLOAD

Medical Travel Letter.

Travel Letter

Print this form and have your patient fill it out so that they are always prepared to travel with TAKHZYRO.

DOWNLOAD

Interested in enrolling your patients in the Quick Start Program or OnePath®?

find application forms here

Access sample templates for appealing an insurance denial

explore templates

Information for you

Case Study Brochure of a TAKHZYRO® patient, Andrew.

Patient Case Study: Andrew

See why Andrew decided to start preventive treatment with TAKHZYRO after living for years with untreated swells.

DOWNLOAD

Case Study Brochure of a TAKHZYRO® patient, Danny.

Patient Case Study: Danny, a Trigger-Avoidant Patient

See why Danny, a patient who is trigger avoidant, started preventive treatment with TAKHZYRO after living with a low HAE attack history.

DOWNLOAD

Dosing Flashcard.

Dosing Flashcard

See the available dosing options to help meet patients' changing HAE needs.

DOWNLOAD

Guide on how to prescribe TAKHZYRO®.

TAKHZYRO Prescriber Guide

Learn about one of the largest prevention studies in HAE with the longest active treatment duration.1-5

DOWNLOAD

TAKHZYRO® Conversation Starter.

Doctor Discussion Guide

See how your patients might start the conversation about TAKHZYRO.

DOWNLOAD

HAE Attack Plan.

HAE Attack Plan

Fill out this form with your patient to help them explain HAE to others, including what steps to take in the event of an emergency.

DOWNLOAD

Information for your patients

TAKHZYRO® Brochure.

TAKHZYRO Brochure

Learn all about TAKHZYRO, from study results to dosing information and more.

DOWNLOAD DESCARGAR

TAKHZYRO® Pediatric Brochure.

TAKHZYRO Pediatric Brochure

Guide caregivers through helpful information about HAE and useful tips on how they can support their loved ones taking TAKHZYRO.

DOWNLOAD DESCARGAR

Getting Started With TAKHZYRO® Brochure.

Getting Started with TAKHZYRO Brochure

Get an overview of what to expect when starting a patient on treatment with TAKHZYRO.

DOWNLOAD DESCARGAR

Prescribing Information for TAKHZYRO®.

TAKHZYRO Instructions for Use Prescribing Information

Explore the Prescribing Information, and ask your patient if they have any questions about taking TAKHZYRO.

DOWNLOAD DESCARGAR

Encourage patient education

Your patients might benefit from seeing how others are living the TAKHZYRO experience. Encourage them to explore our video gallery.

Patients can watch here

Some of your patients may need help remembering to take TAKHZYRO as prescribed. Encourage them to sign up for dosing reminders.

Patients can sign up here
US Hereditary Angioedema Association logo.

Your patients with HAE can continue to explore resources and connect with support offered through the US Hereditary Angioedema Association (HAEA).

Visit haea.org

Looking for more resources to support your patients and your practice?

Sign up for emails

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. doi:10.1111/all15011 3. Cinryze. Prescribing information. Takeda Pharmaceuticals; 2023. 4. Haegarda. Prescribing information. CSL Behring LLC; 2022. 5. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc; 2022.